KHPG(SZ:002773) 智通财经网·2025-12-08 00:11Core Viewpoint - Kanghong Pharmaceutical's eye injection, Conbercept (brand name "Langmu"), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), reflecting the recognition of its innovative results and clinical value by the National Healthcare Security Administration [1] Group 1 - Conbercept is the only domestic innovative drug in the catalog that covers four major indications for retinal diseases [1] - The inclusion in the regular catalog management will enhance the stability and accessibility of medication for patients [1] - The company is actively conducting Phase III clinical trials for high-dose Conbercept and clinical trials for gene therapy drugs KH631 and KH658 in both China and the United States [1]